Biolife Solutions (BLFS) Common Equity (2010 - 2026)

Biolife Solutions (BLFS) has reported Common Equity for 17 consecutive years, with $420.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 20.98% year-over-year to $420.0 million in Q2 2026; TTM through Jun 2026 was $420.0 million, a 20.98% increase from a year earlier, with the FY2025 full-year figure at $371.9 million, up 6.59% from the prior year.
• Common Equity was $420.0 million for Q2 2026 at Biolife Solutions, up from $372.2 million in the prior quarter.
• Over five years, Common Equity peaked at $476.1 million in Q1 2022 and troughed at $321.4 million in Q2 2024.
• A 5-year average of $365.6 million and a median of $353.2 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 128.03% in 2022 and declined 24.78% in 2023, its largest moves.
• Over 5 years, Common Equity stood at $364.2 million in 2022, then dropped by 7.28% to $337.7 million in 2023, then gained by 3.33% to $348.9 million in 2024, then advanced by 6.59% to $371.9 million in 2025, then increased by 12.94% to $420.0 million in 2026.
• The last three Common Equity figures came in at $420.0 million (Q2 2026), $372.2 million (Q1 2026), and $371.9 million (Q4 2025), per Business Quant data.